Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure resultsOct 2Weekly roundup, 5 itemsALN-CIDEBamrecibartUpdated
Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody studyJun 30Weekly roundup, 2 itemsfreneslerbartmevonlerbart